Thus, to provide clarity to these application relevant questions, and to potentially uncover neuroblastoma antigens, we performed a W6/32-based immunopeptidomics campaign on six of the seven neuroblastoma cell lines we evaluated initially, which span baseline HLA-I levels and tapasin-TM–mediated effects on HLA-I expression, and stability (Figs. 2F and 3). Here, TAPBP is linked to neuroblastoma.